5 DMD Data Readouts to Watch in 2024

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 6, 2024 at 11:32 AM.

  1. #1 cafead, May 6, 2024 at 11:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,332
    Likes Received:
    3
    via The March approval of ITF Therapeutics’ Duvyzat marked the third new FDA-approved treatment in 10 months for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle weakness and degeneration. In June 2023, the regulator greenlit Sarepta’s Elevidys as the first-ever gene therapy for DMD. That approval was followed by Santhera Pharmaceuticals’ novel corticosteroid Agamree in October.

    article source
     
    Quote

Reply to Thread